Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Markets

<< Previous

Bullboard Posts

Next >>

Comment by Doccoleon May 21, 2021 8:29am

121 Views

Post# 33246699

RE:RE:RE:RE:RE:RE:RE:RE:Markets

I don't think covid is going to be a issue for the study. I was worried, but all our American hospitals are being told business as usual within 3 months.

ATE being aligned with AH is huge. I am glad that's done. I anticipate a LATAM deal announced within 2 months with GUD.

<< Previous

Bullboard Posts

Next >>

The Market Online’s Weekly Cannabis Report – Nov. 15, 2024